Engagement in care among women and their infants lost to follow-up under Option B+ in eSwatini.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2019
2019
Historique:
received:
30
04
2019
accepted:
10
09
2019
entrez:
31
10
2019
pubmed:
31
10
2019
medline:
12
3
2020
Statut:
epublish
Résumé
Universal antiretroviral treatment (ART) for pregnant women with HIV, Option B+, has been adopted widely for prevention of mother-to-child HIV transmission (PMTCT). Some evidence shows high loss to follow-up (LTF) under this model. However, gaps in data systems limit this evidence. We collected additional information for women and infants LTF from Option B+ in Eswatini to assess more accurate outcomes. LTF at 6-months postpartum was assessed using facility data. Additional data was gathered from: 1) the national ART database and paper records; 2) patient tracing; and 3) interviews and abstraction from patient-held records. Engagement in care was defined as any clinic visit within 91 days before or after 6-months postpartum or completion of a documented transfer; or, for those traced but not completing study interviews, visits at 6-months postpartum or later (for infants), or visits within 3-months of tracing (for women). Multivariable loglinear models were used to identify correlates of engagement. One-hundred-ninety-four (44.7%) of 434 LTF women had outcomes ascertained, including 122 (62.9%) women engaged in care. Among 510 LTF infants, 265 (52.0%) had ascertained outcomes, including 143 (54.0%) engaged in care, 47 (17.7%) pregnancy losses, and 18 (6.8%) deaths. Seventy-two of 189 live infants (38.1%) with ascertained outcomes had a 6-week early infant diagnostic (EID) test. Among women with ascertained outcomes, gestational age of 20+ weeks (vs. fewer than 20 weeks, aRR 0.80; 95% CI 0.68-0.94) and age 25-29 years (vs. 15-24 years, aRR 0.81; 95% CI 0.67-0.97), were associated with lower engagement; initiating ART after first ANC visit was associated with higher engagement (vs. at first ANC visit, aRR 1.12; 95% CI 1.04-1.21). Among infants with ascertained outcomes, mother not initiating ART was associated with lower engagement (vs. ART at first ANC visit, aRR 0.71; 95% CI 0.54-0.91). Substantial numbers of women and infants classified as LTF under Option B+ were engaged in care, though a suboptimal level of 6-week EID testing was observed. These findings highlight a need to improve coverage of routine EID testing, and improve data systems to better capture PMTCT patient outcomes.
Sections du résumé
BACKGROUND
Universal antiretroviral treatment (ART) for pregnant women with HIV, Option B+, has been adopted widely for prevention of mother-to-child HIV transmission (PMTCT). Some evidence shows high loss to follow-up (LTF) under this model. However, gaps in data systems limit this evidence. We collected additional information for women and infants LTF from Option B+ in Eswatini to assess more accurate outcomes.
METHODS
LTF at 6-months postpartum was assessed using facility data. Additional data was gathered from: 1) the national ART database and paper records; 2) patient tracing; and 3) interviews and abstraction from patient-held records. Engagement in care was defined as any clinic visit within 91 days before or after 6-months postpartum or completion of a documented transfer; or, for those traced but not completing study interviews, visits at 6-months postpartum or later (for infants), or visits within 3-months of tracing (for women). Multivariable loglinear models were used to identify correlates of engagement.
RESULTS
One-hundred-ninety-four (44.7%) of 434 LTF women had outcomes ascertained, including 122 (62.9%) women engaged in care. Among 510 LTF infants, 265 (52.0%) had ascertained outcomes, including 143 (54.0%) engaged in care, 47 (17.7%) pregnancy losses, and 18 (6.8%) deaths. Seventy-two of 189 live infants (38.1%) with ascertained outcomes had a 6-week early infant diagnostic (EID) test. Among women with ascertained outcomes, gestational age of 20+ weeks (vs. fewer than 20 weeks, aRR 0.80; 95% CI 0.68-0.94) and age 25-29 years (vs. 15-24 years, aRR 0.81; 95% CI 0.67-0.97), were associated with lower engagement; initiating ART after first ANC visit was associated with higher engagement (vs. at first ANC visit, aRR 1.12; 95% CI 1.04-1.21). Among infants with ascertained outcomes, mother not initiating ART was associated with lower engagement (vs. ART at first ANC visit, aRR 0.71; 95% CI 0.54-0.91).
CONCLUSION
Substantial numbers of women and infants classified as LTF under Option B+ were engaged in care, though a suboptimal level of 6-week EID testing was observed. These findings highlight a need to improve coverage of routine EID testing, and improve data systems to better capture PMTCT patient outcomes.
Identifiants
pubmed: 31665137
doi: 10.1371/journal.pone.0222959
pii: PONE-D-19-12245
pmc: PMC6821080
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0222959Subventions
Organisme : NIAID NIH HHS
ID : R21 AI120690
Pays : United States
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
J Int AIDS Soc. 2017 Sep 04;20(1):21947
pubmed: 28884524
J Acquir Immune Defic Syndr. 2018 Apr 15;77(5):427-438
pubmed: 29287029
J Acquir Immune Defic Syndr. 2015 Nov 1;70(3):e102-9
pubmed: 26470033
Clin Infect Dis. 2016 Aug 1;63(3):426-7
pubmed: 27165659
J Int AIDS Soc. 2014 Jun 11;17:18914
pubmed: 24925044
AIDS. 2014 Feb 20;28(4):589-598
pubmed: 24468999
J Int AIDS Soc. 2018 Jul;21 Suppl 4:e25114
pubmed: 30027583
Trop Med Int Health. 2014 Nov;19(11):1360-6
pubmed: 25087778
J Acquir Immune Defic Syndr. 2014 Dec 1;67 Suppl 4:S188-94
pubmed: 25436817
J Acquir Immune Defic Syndr. 2017 Apr 1;74(4):383-389
pubmed: 28225717
Trop Med Int Health. 2015 Mar;20(3):365-79
pubmed: 25418366
PLoS One. 2009 Jun 04;4(6):e5790
pubmed: 19495419
Int J STD AIDS. 2018 Feb;29(2):185-194
pubmed: 28750577
Trop Med Int Health. 2010 Jun;15 Suppl 1:63-9
pubmed: 20586962
Curr Opin HIV AIDS. 2013 Sep;8(5):474-89
pubmed: 23925003
AIDS. 2014 Feb 20;28(4):599-601
pubmed: 24469000
BMC Med Res Methodol. 2017 Sep 6;17(1):134
pubmed: 28877666
Trop Med Int Health. 2017 Apr;22(4):375-387
pubmed: 28102610
J Acquir Immune Defic Syndr. 2017 May 1;75 Suppl 1:S51-S58
pubmed: 28398997
PLoS One. 2017 Jun 21;12(6):e0179838
pubmed: 28636669
AIDS Behav. 2017 Jul;21(Suppl 1):15-22
pubmed: 28401415
AIDS. 2019 Jan 27;33(1):45-54
pubmed: 30289804
BMC Infect Dis. 2018 Oct 24;18(1):533
pubmed: 30355356